RBC Capital: 'Miebo remains the second-largest Rx DED drug in the US with 22.8% market share'
Tweet Send to a Friend
RBC Capital analyst Douglas Miehm reiterated an Outperform rating and $21.00 price target on Bausch & Lomb Corp. (NYSE: BLCO).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
